PATENT CLAIM ANALYSIS

Application Number: 15777340
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "134100"]

Abstract:
The disclosure provides fusion polypeptides comprising a moiety specific for Ang-2 and another for VEGF-A, which fusion polypeptide can be useful for antagonizing Ang-2 and VEGF-A. In a preferred embodiment, the Ang-2-specific moiety is comprised of a human neutrophil gelatinase associated lipocalin (hNGAL) mutein. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as an agent useful to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making the fusion polypeptides described herein as well as compositions comprising such fusion polypeptides. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptides, their amino acid sequences and to methods for the generation of such fusion polypeptides and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.

Claim (Index 14):
The fusion polypeptide of  claim 1 , wherein said mutein comprises one of the following sets of mutated amino acid residues in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO: 1):\n (a) Leu 36\u2192Gln; Ala 40\u2192Tyr; Gln49\u2192Gly; Tyr 52\u2192Trp; Ser 68\u2192Gly; Leu 70\u2192Ser; Arg 72\u2192Gly; Lys 73\u2192Pro; Asp 77\u2192Asn; Trp 79\u2192Thr; Arg 81\u2192Trp; Asn 96\u2192Gly; Tyr 100\u2192Pro; Leu 103\u2192Gly; Tyr 106\u2192Thr; Lys 125\u2192His; Ser 127\u2192Leu; Tyr 132\u2192Phe; Lys 134\u2192Glu; (b) Leu 36\u2192Phe; Ala 40 His; Ile 41\u2192Arg; Gln 49\u2192Gly; Tyr 52\u2192His; Ser 68\u2192Asp; Leu 70\u2192Thr; Arg 72\u2192Ala; Lys 73\u2192Phe; Asp 77\u2192Asn; Trp 79\u2192Arg; Arg 81\u2192His; Tyr 100\u2192Trp; Leu 103\u2192Glu; Tyr 106\u2192Thr; Lys 125\u2192Thr; Ser 127\u2192Met; Tyr 132\u2192Trp; Lys 134\u2192Trp; (c) Leu 36\u2192Val; Ala 40\u2192Trp; Ile 41\u2192Tyr; Gln 49\u2192Ile; Tyr 52\u2192Thr; Ser 68\u2192Gln; Leu 70\u2192Gly; Arg 72\u2192Glu; Lys 73\u2192Gln; Asp 77\u2192Lys; Trp 79\u2192Ser; Arg 81\u2192His; Tyr 100\u2192Trp; Leu 103\u2192Asp; Tyr 106\u2192Leu; Lys 125\u2192Gly; Ser 127\u2192Met; Tyr 132\u2192Val; Lys 134\u2192Ala; (d) Leu 36\u2192Glu, Ala 40 Val; Ile 41\u2192Glu; Gln 49\u2192Val; Tyr 52 Thr; Ser 68\u2192Glu; Leu 70\u2192Arg; Arg 72\u2192Trp; Lys 73\u2192Leu; Asp77\u2192Lys; Trp 79\u2192Asn; Arg 81\u2192His; Asn 96\u2192Ala; Tyr 100\u2192Gly; Leu 103\u2192Met; Tyr 106\u2192Thr; Lys 125\u2192Thr; Ser 127\u2192Met; Tyr 132\u2192Trp; Lys 134\u2192Trp; (e) Leu 36\u2192Gln; Ala 40\u2192Tyr; Ile 41\u2192Trp; Gln 49\u2192Ile; Tyr 52\u2192Ser; Ser 68\u2192Ile; Leu 70\u2192Tyr; Arg 72\u2192Thr; Lys 73\u2192Arg; Asp 77\u2192Ser; Trp 79\u2192Arg; Arg 81\u2192Tyr; Asn 96\u2192Pro; Leu 103\u2192Asp; Tyr 106\u2192Thr; Lys 125\u2192His; Ser 127\u2192Tyr; Tyr 132\u2192Trp; Lys 134\u2192Glu; (f) Leu 36\u2192Gln; Ala 40\u2192Tyr; Gln 49\u2192Glu; Tyr 52\u2192Trp; Asn 65\u2192Asp; Ser 68\u2192Gly; Leu 70\u2192Ser; Arg 72\u2192Gly; Lys 73\u2192Pro; Asp 77\u2192Asn; Trp 79\u2192Arg; Arg 81\u2192Trp; Asn 96\u2192Gly; Tyr 100\u2192Ser; Leu 103\u2192Gln; Tyr 106\u2192Thr; Lys 125\u2192His; Ser 127\u2192Leu; Tyr 132\u2192Phe; Lys 134\u2192Glu; (g) Leu 36\u2192His; Ala 40 Tyr; Gln 49\u2192Glu; Tyr 52\u2192Trp; Asn 65\u2192Asp; Ser 68\u2192Glu; Leu 70\u2192Ser; Arg 72\u2192Gly; Lys 73\u2192Pro; Asp 77\u2192Asn; Trp 79\u2192Arg; Arg 81\u2192Trp; Asn 96\u2192Gly; Tyr 100\u2192Pro; Leu 103\u2192Asp; Tyr 106\u2192Thr; Lys 125\u2192His; Ser 127\u2192Leu; Tyr 132\u2192Phe; Lys 134\u2192Glu; (h) Leu 36\u2192Gln; Ala 40 Tyr; Gln 49\u2192Gly; Tyr 52 Trp; Asn 65\u2192Asp; Ser 68\u2192Glu; Leu 70\u2192Ser; Arg 72\u2192Gly; Lys 73\u2192Ala; Asp 77\u2192Asn; Trp 79\u2192Arg; Arg 81\u2192Trp; Asn 96\u2192Gly; Tyr 100\u2192Asp; Leu 103\u2192Gly; Tyr 106\u2192Thr; Lys 125\u2192His; Ser 127\u2192Leu; Tyr 132\u2192Phe; Lys 134\u2192Glu; (i) Leu 36\u2192His; Ala 40 Tyr; Gln 49\u2192Gly; Tyr 52 Trp; Asn 65\u2192Asp; Ser 68\u2192Glu; Leu 70\u2192Ser; Arg 72\u2192Gly; Lys 73\u2192Pro; Asp 77\u2192Asn; Trp 79\u2192Arg; Arg 81\u2192Trp; Asn 96\u2192Gly; Tyr 100\u2192Pro; Leu 103\u2192Gly; Tyr 106\u2192Thr; Lys 125\u2192His; Ser 127\u2192Leu; Tyr 132\u2192Phe; Lys 134\u2192Glu; (j) Leu 36\u2192Gln; Ala 40 Tyr; Gln 49\u2192Gly; Tyr 52 Trp; Asn 65\u2192Asp; Ser 68\u2192Gly; Leu 70\u2192Ser; Arg 72\u2192Gly; Lys 73\u2192Ala; Asp 77\u2192Val; Trp 79\u2192Arg; Arg 81\u2192Trp; Asn 96\u2192Gly; Tyr 100\u2192Pro; Leu 103\u2192Gly; Tyr 106\u2192Thr; Lys 125\u2192His; Ser 127\u2192Leu; Tyr 132\u2192Phe; Lys 134\u2192Glu; (k) Leu 36\u2192Gln; Ala 40 Tyr; Gln 49\u2192Val; Tyr 52 Trp; Asn 65\u2192Asp; Ser 68\u2192Glu; Leu 70\u2192Ser; Arg 72\u2192Gly; Lys 73\u2192Pro; Asp 77\u2192Asn; Trp 79\u2192Arg; Arg 81\u2192Trp; Asn 96\u2192Gly; Tyr 100\u2192Leu; Leu 103\u2192Gly; Tyr 106\u2192Thr; Lys 125\u2192His; Ser 127\u2192Leu; Tyr 132\u2192Phe; Lys 134\u2192Glu; (l) Leu 36\u2192Val; Ala 40 Tyr; Ile 41\u2192Tyr; Gln 49\u2192Ile; Tyr 52 Thr; Asn 65\u2192Asp; Ser 68\u2192Gln; Leu 70\u2192Gly; Arg 72\u2192Glu; Lys 73\u2192Gln; Lys 74\u2192Glu; Asp 77\u2192Lys; Trp 79\u2192Ser; Arg 81\u2192His; Tyr 100\u2192Trp; Leu 103\u2192Asp; Tyr 106\u2192Pro; Asn 116\u2192Asp; Lys 125\u2192Gly; Ser 127\u2192Met; Asn 129\u2192Asp; Tyr 132\u2192Val; Lys 134\u2192Ala; (m) Leu 36\u2192Val; Ala 40 Tyr; Ile 41\u2192Tyr; Gln 49\u2192Ile; Tyr 52 Thr; Asn 65\u2192Asp; Ser 68\u2192Gln; Leu 70\u2192Gly; Arg 72\u2192Glu; Lys 73\u2192Gln; Lys 74\u2192Glu; Asp 77\u2192Lys; Trp 79\u2192Ser; Arg 81\u2192His; Asn 96\u2192Asp; Tyr 100\u2192Trp; Leu 103\u2192Asp; Tyr 106\u2192Pro; Lys 125\u2192Gly; Val 126\u2192Met; Ser 127\u2192Met; Asn 129\u2192Asp; Tyr 132\u2192Val; Lys 134\u2192Ala; and (n) Leu 36\u2192Met; Ala 40 Tyr; Ile 41\u2192Asp; Gln 49\u2192Ile; Tyr 52\u2192Thr; Asn 65\u2192Asp; Ser 68\u2192Gln; Leu 70\u2192Gly; Arg 72\u2192Glu; Lys 73\u2192Gln; Asp 77\u2192Lys; Trp 79\u2192Ser; Arg 81\u2192His; Asn 96\u2192Gln; Tyr 100\u2192Trp; Leu 103\u2192Asp; Tyr 106\u2192Pro; Lys 125\u2192Gly; Ser 127\u2192Met; Tyr 132\u2192Val; Lys 134\u2192Ala; wherein each of the sets of mutated amino acid residues optionally further includes the mutations Gln 28\u2192His and Cys 87\u2192Ser.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 93.0
- Lexical Diversity: 1.87952
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15546609', '15371698', '13885229', '13816808', '15575271']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8452781460946265
- 35 USC 102 Novelty (BERT): 0.7285011221123618
- Combined Prediction Score: 0.8336004436964
- Mean Citation Score: 700.28126
- Max Citation Score: 837.4807
- Similarity Product: 785.1436472013593

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test